Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Collins

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Vaccine|October 10, 2013
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young childrenJanet A Englund, Ruth A Karron, Coleen K Cunningham, et al.
Journal of Virology|May 26, 2017
Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine CandidateBo Liang, Joan O Ngwuta, Sonja Surman, et al.
The Journal of Infectious Diseases|January 21, 2006
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humansPeter F Wright, Ruth A Karron, Shabir A Madhi, et al.
The Journal of Infectious Diseases|March 7, 2018
Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and ChildrenUrsula J Buchholz, Coleen K Cunningham, Petronella Muresan, et al.
The Journal of Infectious Diseases|February 2, 2020
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Journal of Infectious Diseases|March 7, 2018
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
Journal of Virology|September 2, 2016
Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus VectorBo Liang, Joan O Ngwuta, Richard Herbert, et al.
NEJM Evidence|August 26, 2025
Live-Attenuated Intranasal RSV Vaccine in Infants and ToddlersOlubukola T Idoko, Sergio L Vargas, Agustin Bueso, et al.
The Journal of Infectious Diseases|June 22, 2022
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenColeen K Cunningham, Ruth A Karron, Petronella Muresan, et al.
Science Translational Medicine|July 15, 2021
Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effectsMichelle Meyer, Bronwyn M Gunn, Delphine C Malherbe, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Vaccine|October 10, 2013
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young childrenJanet A Englund, Ruth A Karron, Coleen K Cunningham, et al.
Journal of Virology|May 26, 2017
Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine CandidateBo Liang, Joan O Ngwuta, Sonja Surman, et al.
The Journal of Infectious Diseases|January 21, 2006
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humansPeter F Wright, Ruth A Karron, Shabir A Madhi, et al.
The Journal of Infectious Diseases|March 7, 2018
Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and ChildrenUrsula J Buchholz, Coleen K Cunningham, Petronella Muresan, et al.
The Journal of Infectious Diseases|February 2, 2020
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Journal of Infectious Diseases|March 7, 2018
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
Journal of Virology|September 2, 2016
Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus VectorBo Liang, Joan O Ngwuta, Richard Herbert, et al.
NEJM Evidence|August 26, 2025
Live-Attenuated Intranasal RSV Vaccine in Infants and ToddlersOlubukola T Idoko, Sergio L Vargas, Agustin Bueso, et al.
The Journal of Infectious Diseases|June 22, 2022
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenColeen K Cunningham, Ruth A Karron, Petronella Muresan, et al.
Science Translational Medicine|July 15, 2021
Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effectsMichelle Meyer, Bronwyn M Gunn, Delphine C Malherbe, et al.
Pageof 25